Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anisodine Hydrobromide Tablets for NAION (Randomized Double-blind Placebo-controlled Phase 4 Study)
ChiCTR2500105158Phase 4Not yet recruiting
- Sponsor
- First Medical Center of Chinese PLA General Hospital
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in non-arteritic anterior ischemic optic neuropathy (NAION) comparing Anisodine hydrobromide + standard therapy with Placebo + standard therapy (2 arms). Primary endpoint: Best-corrected visual acuity (BCVA). Planned start Jun 2025; status: not yet recruiting.
02
Drugs
anisodine
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on ChiCTR2500105158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105158.